John D. Lee

Array ( [id] => 10186823 [patent_doc_number] => 09216229 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-22 [patent_title] => 'IgE CH3 peptide vaccine' [patent_app_type] => utility [patent_app_number] => 13/904432 [patent_app_country] => US [patent_app_date] => 2013-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 61174 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13904432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11915437 [patent_doc_number] => 09783614 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-10 [patent_title] => 'Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/400281 [patent_app_country] => US [patent_app_date] => 2013-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 31 [patent_no_of_words] => 23376 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14400281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9173912 [patent_doc_number] => 20130315897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor' [patent_app_type] => utility [patent_app_number] => 13/889982 [patent_app_country] => US [patent_app_date] => 2013-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 15349 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13889982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9306100 [patent_doc_number] => 20140044773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-13 [patent_title] => 'ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/889014 [patent_app_country] => US [patent_app_date] => 2013-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 36409 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13889014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9306100 [patent_doc_number] => 20140044773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-13 [patent_title] => 'ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/889014 [patent_app_country] => US [patent_app_date] => 2013-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 36409 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13889014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9147791 [patent_doc_number] => 20130302314 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'ANTI-C EPSILON MX ANTIBODIES CAPABLE OF BINDING TO HUMAN MIGE ON B LYMPHOCYTES' [patent_app_type] => utility [patent_app_number] => 13/888913 [patent_app_country] => US [patent_app_date] => 2013-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 4853 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13888913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9306100 [patent_doc_number] => 20140044773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-13 [patent_title] => 'ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/889014 [patent_app_country] => US [patent_app_date] => 2013-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 36409 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13889014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9306100 [patent_doc_number] => 20140044773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-13 [patent_title] => 'ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/889014 [patent_app_country] => US [patent_app_date] => 2013-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 36409 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13889014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11575782 [patent_doc_number] => 09631030 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-25 [patent_title] => 'Administering antibodies or fragments thereof which bind hemopexin for the treatment of ocular diseases' [patent_app_type] => utility [patent_app_number] => 14/398110 [patent_app_country] => US [patent_app_date] => 2013-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 5374 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14398110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8964365 [patent_doc_number] => 20130203967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-08 [patent_title] => 'NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 13/860500 [patent_app_country] => US [patent_app_date] => 2013-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 33156 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13860500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8964363 [patent_doc_number] => 20130203966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-08 [patent_title] => 'NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 13/860484 [patent_app_country] => US [patent_app_date] => 2013-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 33135 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13860484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13079439 [patent_doc_number] => 10059777 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-28 [patent_title] => Secretory immunoglobulin complex [patent_app_type] => utility [patent_app_number] => 14/390755 [patent_app_country] => US [patent_app_date] => 2013-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 17 [patent_no_of_words] => 27958 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14390755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9081036 [patent_doc_number] => 20130266566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'METHODS OF INHIBITING FIBROSIS USING ANTI-PAI-1 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/848197 [patent_app_country] => US [patent_app_date] => 2013-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 72 [patent_no_of_words] => 110828 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13848197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9068107 [patent_doc_number] => 20130259864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-03 [patent_title] => 'Anti-Cobra Toxin Antibody Fragments and Method of Producing a VHH Library' [patent_app_type] => utility [patent_app_number] => 13/845673 [patent_app_country] => US [patent_app_date] => 2013-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 16413 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13845673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9857804 [patent_doc_number] => 20150037821 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-05 [patent_title] => 'METHODS OF IDENTIFYING HIT-ANTIBODIES AND PF4 ANTAGONISTS AND CELL LINES FOR USE THEREIN' [patent_app_type] => utility [patent_app_number] => 14/386852 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13648 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9747437 [patent_doc_number] => 20140283157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/839041 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30517 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13839041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10649419 [patent_doc_number] => 09365655 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-14 [patent_title] => 'Soluble heavy-chain only antibodies' [patent_app_type] => utility [patent_app_number] => 13/815812 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 18859 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13815812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9476694 [patent_doc_number] => 20140134157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-15 [patent_title] => 'ANTIBODIES TO OPGL' [patent_app_type] => utility [patent_app_number] => 13/831099 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 26402 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13831099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9849801 [patent_doc_number] => 08951525 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-10 [patent_title] => 'Human tissue factor antibody and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/803887 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 21738 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13803887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11480503 [patent_doc_number] => 09587034 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-07 [patent_title] => 'Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains' [patent_app_type] => utility [patent_app_number] => 14/395572 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 10 [patent_no_of_words] => 17953 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14395572 [rel_patent_id] =>[rel_patent_doc_number] =>)